Last reviewed · How we verify

NCT05196867

Liver Cancer Prevention Randomized Control Trial

Active, enrolled NA Last updated 24 February 2026
What this trial tests

NA trial testing Intervention Group in Liver Diseases in 49 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
11 February 2022
Primary endpoint
30 August 2028
30 August 2028

Quick facts

Lead sponsorM.D. Anderson Cancer Center
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment49
Start date11 February 2022
Primary completion30 August 2028
Estimated completion30 August 2028
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Liver Diseases or Fibrosis, Liver. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the effectiveness of a behaviorally-based tailored disease management intervention in patients with fibrosis or steatosis and risk factors for cirrhosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Intervention Group

Trials testing the same drug.

Other recruiting trials for Liver Diseases

Currently open trials in the same condition.

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05196867.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing